Brigham Renal Division Research at the Center of an International Effort to Identify Next Generation Biomarkers to Screen Kidney Toxicity
Press Release - May 14, 2010
http://www.brighamandwomens.org/Pressreleases/PressRelease.aspx?PageID=679
Brigham Renal Division Research at the Center of an International Effort to Identify Next Generation Biomarkers to Screen Kidney Toxicity
Boston, MA – The kidney is one of the primary targets for toxicity of drugs. Two serum biomarkers, serum creatinine (SCr) and blood urea nitrogen (BUN), are commonly used to detect kidney toxicity in preclinical and clinical studies and in routine clinical care. Both, however, have severe limitations relating to sensitivity and specificity.
New research from the laboratories of Vishal S. Vaidya, a Faculty in the Renal Division at Brigham and Women’s Hospital (BWH) and Assistant Professor of Medicine at HMS and Joseph V. Bonventre, the Samuel A. Levine Professor of Medicine, Health Sciences and Technology at HMS and chief of the renal division at BWH in collaboration with the Predictive Safety Testing Consortium, has resulted in the approval of Kidney Injury Molecule-1 (Kim-1) as a highly sensitive and specific marker of drug-induced kidney injury by both the FDA and EMA and is expected to greatly facilitate evaluation of tubular toxicity in certain preclinical and clinical settings.
Posted by Vishal Vaidya on Fri, 14 May 2010